Experts Urge Stopping Melanoma Trial Because of Failure and Harm Experts Urge Stopping Melanoma Trial Because of Failure and Harm

New results from a phase 3 trial may shut the door on the addition of PD –1 or PD–ligand 1 inhibitors to the combination of BRAF and MEK inhibitors for the treatment of BRAF V600–mutated melanoma.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news